cyrilzakka/clinical-trials huggingface dataset:
TaVNS Improves the Symptoms of Patients With Moderate to Severe CP/CPPS

This trial aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) for moderate to severe chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). This study is a prospective, randomized, controlled trial. A total of 68 patients with CP/CPPS will be recruited. After baseline assessment, the patients will be randomized into taVNS group (n = 34) and sham-taVNS group (n = 34). The intervention of two group will last for 4 weeks with a 8-week follow-up period after the treatment. The National Institutes of Health chronic Prostatitis Symptom Score index (NIH-CPSI), International Prostate Symptom Score Scale (IPSS), European quality of Life-5 Dimensions Questionnaire (EQ-5D), self-rating anxiety Scale (SAS) and self-rating depression scale (SDS) will be assessed. The adverse events during the whole study will be recorded detailedly.


Eligibility Criteria:
Inclusion Criteria:

* Consistent with the diagnostic criteria of CP/CPPS of EAU or CAU, the clinical manifestations were recurrent and persistent prostate pain accompanied by abnormal urination and psychiatric symptoms, without infection or other obvious pathological conditions. The pain symptoms were mainly manifested as pain in the surrounding tissues centered on the prostate, and pain, swelling or discomfort in the scrotum, testis, lower abdomen, perineum, lumbosacral area, and medial thigh. Abnormal urination was characterized by frequent urination, urgent urination, urination pain, urethral burning, residual urination or white discharge from the urethra at the end of urination or defecation in the morning. The neuropsychiatric symptoms included dizziness and tinnitus, insomnia and dreams, anxiety and depression, and even impotence, premature ejaculation, and spermatorrhea. Symptoms lasting more than 3 months in the last six months
* 18 ≤ Age ≤ 50 years old
* NIH-CPSI ≥15 (patients with moderate to severe CP/CPPS)
* Signed informed consent and voluntarily participated in the trial

Exclusion Criteria:

* Patients with other diseases that cause urinary symptoms were excluded: Such as benign prostatic hyperplasia, testicular and epididymal and spermatic cord diseases, overactive bladder, neurogenic bladder, interstitial cystitis, glandular cystitis, sexually transmitted diseases, bladder tumors such as carcinoma in situ, prostate cancer, urinary male reproductive system tuberculosis, anorectal diseases, lumbar diseases, central and peripheral neuropathy, etc
* Patients with severe diseases of the heart, liver, kidney, hematopoietic system and poor nutritional status
* Patients with severe mental and emotional disorders, who were unable to cooperate with the study
* Patients who have been treated with CP/CPPS regimen in the past 4 weeks
Comparison of the Quantity of Distal Movement of the Upper Canine and Molar

THE PURPOSE OF THE STUDY IS COMPARE THE QUANTITY OF DISTAL MOVEMENT OF THE UPPER CANINE AND MOLAR USING CLASS II ELASTICS WITH AND WITHOUT SLIDING JIG IN A PERIOD OF 3 MONTHS

To achieve a Class I canine relationship at the end of the alignment and leveling phase, different intraoral devices have been used. These include intermaxillary class II elastics, which retract the upper and protract the lower arch, generating extrusive forces at the anchorage sites. Its upper distalizing action is exerted to the canine bracket and transmitted through the posterior teeth where the upper molar does not receive a direct force. The sliding jig is an auxiliary addition that exerts force to the molar by an elastic hanged in a jig between the lateral and the canine in class II; such mechanism decreases the vertical adverse effects of the elastics wearing while directing the distalizing force to the molar.

A randomized, unblinded, clinical trial comparing 30 units of analysis (hemi arches) in which were placed sliding jig or stand alone elastics were perform.

Eligibility Criteria:
Inclusion Criteria:

* Class II dental malocclusion with alignment and leveling phase ended.
* Root completed not trauma
* Second molar erupted
* Third molar absent
* Dental and periodontal health

Exclusion Criteria:

* Root uncompleted
* Dental Trauma
* Dental Pathology
Anterior Cruciate Ligament Pain Study

The objective of this study is to compare the pain control benefit of two different types of nerve blocks in patients undergoing anterior cruciate ligament (ACL) reconstruction.

This trial is a prospective, randomized, surgeon-blinded, two-armed trial to investigate the safety and efficacy of femoral nerve blocks versus adductor canal blocks for participants undergoing outpatient anterior cruciate ligament (ACL) reconstruction surgery.

The objective of this study is to compare the pain control benefit of two different types of nerve blocks. Ropivacaine, which is FDA-approved for use in both femoral nerve blocks as well as adductor canal blocks, will be utilized. The study will be comparing the efficacy between FDA approved treatments.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing scheduled anterior cruciate ligament (ACL) surgery at the Emory Orthopaedic and Spine Center
* Patients willing and able to provide written informed consent
* Parents willing and able to provide written informed consent for minors

Exclusion Criteria:

* Patients who are pregnant or lactating
* Patients with liver dysfunction or renal failure
* Patients with a known allergy to ropivacaine
* Patients with a local infection
* Patients who take chronic pain medications
* Patients with an opioid tolerance
* Patients with known coagulopathy or bleeding risk.
* Patients who are getting neuraxial anesthesia for surgery
Double and Single Intrauterine Insemination In Controlled Ovarian Stimulation (COH) Cycles With Multifollicular Development

Our hypothesis is double insemination will improve pregnancy rates in coh cycles with more than one dominant follicles (\>16mm).

Metaanalysis for the effects of double IUI demonstrates that effects of this procedure is not different from single IUI. It is known that nearly 25% of coh cycles is evident by monofollicular development.For this reason it is possible that this monofollicular cycles in the studies could decrease the effects of double IUI.

Inclusion criteria:

1. Patients with unexplained infertility or mild male factor infertility whom admitted to the COH+IUI programme in our infertility unit.
2. Female age \<37 years old.
3. Baseline FSH \<12 mIU/L
4. Total antral follicle count\>6
5. During the first three cycles of COH+IUI
6. Minimum 2 follicles \>16 mm at the day of HCG.

Primary outcome:

Ongoing pregnancy rates

Secondary outcomes:

The effects of different coh regimens (CC,FSH,CC+FSH)on the outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Unexplained and mild male factor infertile patients
* Minimum 2 follicles \>16 mm at the day of HCG
* First 3 cycles

Exclusion Criteria:

* Basal FSH \>12 mIU/L
* Total antral follicle count\<6
* Severe male factor infertility
Association Between Type of Ligating Brackets and Oral Health-related Quality of Life in Orthodontic Patients

To evaluate the association of the level of quality of life related to oral health, between treatment with the minitube system and conventional ligation brackets, in adult patients with moderate malocclusion, during the first six months, of orthodontic treatment.

This is an observational cohort study with 1: 1 allocation ratio. The sample will be of 200 participants, divided into two groups. People over 18 years of age will be included; with moderate treatment complexity determined by Dental Aesthetics Index DAI. The study interventions are: (1) Mini tube system (FLOW-JAC System, Bogotá, Colombia) and (2) Conventional ligating brackets (Gemini 3M Unitek Orthodontic Products bracket, Calif, USA) with Nitinol Classic or superelastic (SE) archwires 0.014 and 0.016.

The outcome variable is Oral health-related quality of life (OHRQoL) measured with OHIP-S14 Ortho instrument, which was validated in Spanish in patients with orthodontic treatment. Consists of 14 questions that address seven dimensions (functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability and handicap), specifically related to orthodontic treatment. The OHIP-S14 Ortho score is between 0 to 56. Where 0 indicates a positive impact and 56 an unfavorable impact. The questionnaire will be self-administered online during the first 6 months of treatment: T0: prior to cementation, T1: 24 -48 hours after cementation, T2: 1 month after cementation, T3: 3 months after cementation and T4: 6 months after cementation.

Eligibility Criteria:
Inclusion Criteria:

* Age range from 18 to 35
* Moderate treatment complexity determined by Dental Aesthetics Index DAI moderate.
* Orthodontic treatment with mini tube system in upper and lower jaw or MBT conventional ligating pre-set appliances
* Non- extractions at the start of orthodontic treatment
* Non- placement of mini-implants at the start of orthodontic treatment

Exclusion Criteria:

* Craniofacial anomalies
* Dental caries at the start of orthodontic treatment
* Periodontal disease at the start of orthodontic treatment
* Systemic disease
* Orthognathic surgery indicated
* Cognitive disorders
* Non understand the Spanish language
Cohort of Swedish Men

The Cohort of Swedish Men began in 1997, when all men born between 1918 and 1952 and residing in two counties in central Sweden received a questionnaire including about 350 items concerning diet and other lifestyle factors. A second questionnaire was sent out in 2008-09.

The Cohort of Swedish Men was established in 1997, when all men born between 1918 and 1952 and residing in Västmanland and Örebro counties in central Sweden received a questionnaire concerning diet and other lifestyle factors. Of the 100,303 eligible men, 48,850 (49%) responded to the questionnaire. The questionnaire included items about diet, physical activity, medical history, and lifestyle factors such as cigarette smoking history and use of dietary supplements.

During 2008-09, the exposure information was updated and extended by sending out two new questionnaires - one questionnaire on health including several signs of symptoms, sleeping, social relations etc (2008) and one on diet, dietary supplement use, and lifestyle factors (2009). Majority of questions in the questionnaires have been validated.

Incident cases of cancer are ascertained by record linkages of the study population with the National Swedish Cancer Register and the Regional Cancer Registers. Cardiovascular and other diseases as well as surgeries and causes of death are identified by linkage to the National Inpatient and other registries at the Swedish Board of Health and Welfare. Ascertainment of cancer cases and other diseases is almost 100% complete. Dates of deaths are ascertained through the Swedish Death Register (100% complete), and information on date of moving out of the study area is obtained by linkage with the Swedish Population Register.

Eligibility Criteria:
Inclusion Criteria:

* All men born between 1918 and 1952, living in central Sweden

Exclusion Criteria:

* None
Statins Evaluation in Coronary Procedures and Revascularization Trial

The purpose of this study is to determine whether a loading dose of atorvastatin before percutaneous intervention procedures in acute coronary syndromes is effective to reduce major cardiovascular events(MACE).

Background: Strategies to reduce complications in acute coronary syndrome treatment have been largely studied. Due to its pleiotropic effects statins are considered an important tool on atherosclerotic plaque stability. Although, the usage of statins before percutaneous coronary intervention in acute coronary syndrome patients, has not yet been demonstrated. Objectives: Evaluate if a loading dose of atorvastatin (80mg) before percutaneous coronary intervention in acute coronary syndrome patients, followed by a reload dose 24 hours, is able to reduce major cardiovascular events (MACE); including combined outcomes such as all-cause mortality, nonfatal acute myocardial infarction, stroke or revascularization with either percutaneous coronary intervention or coronary-artery bypass grafting after 30 days. Methods: Multicentric randomised controlled clinical trial, with allocation concealment and intention to treat analysis. Competitive recruitment will involve 4,192 patients. Acute coronary syndrome patients intending to undergo percutaneous coronary intervention with or without stent placement will be randomized 1:1 to receive either atorvastatin 80mg or placebo before the coronary procedure and also a reload dosage after 24 hours from angioplasty. All patients will collect blood sample to determine CKMB levels pre and post procedure (6 to 12h and 18 to 24 hours). After 30 days, an in person interview will be performed and blood sample will be collected in order to dosage AST, ALT, CPK, and cholesterol levels. Telephonic interview will be done at 6 and 12 months to access occurrence of cardiovascular events.

Eligibility Criteria:
Inclusion Criteria:

* Acute coronary syndrome patients intending to undergo percutaneous coronary intervention.

Exclusion Criteria:

* Younger than 18 years
* Presence of any contraindication to statin (Pregnant women, breast-feeding women or statin hypersensibility)
* Advanced hepatic disease
* Use of statins at the maximum dosage in the last 24 hours before the loading dose of the study drug
* Use of fibrate in the last 24 hours
You Are What You Eat: A Randomised Controlled Trial of an Appearance-based Dietary Intervention

This study investigated whether illustration of the facial appearance benefits of fruit and vegetable consumption is able to motivate increased intake of this food group. The investigators hypothesize that individuals witnessing illustrations of the impact of a healthy diet will exhibit improvements in diet relative to a control group receiving only information on the health-benefits of this food group.


Eligibility Criteria:
Inclusion Criteria:

* Student or staff member at University of St Andrews
* Has access to email account to receive link to weekly online questionnaire.

Exclusion Criteria:

* Exited study before completion
* Unable to make dietary changes due to a medical condition
Prevalence of Pressure Ulcers Among Critically Ill Patients and Factors Associated With Their Occurrence in the ICU

The prevalence of and risk factors for pressure ulcers (PUs) in critically ill patients have been poorly studied. The main objective of this study was to describe the prevalence of PUs in critically ill patients. Secondary objectives were to describe PUs, means of prevention of PUs, and factors associated with occurrence of PUs in the ICU.

Pressure ulcers (PUs) among hospitalized patients are associated with a poor prognosis and with a high cost of care. Hospitalization in the ICU is a context where there is a high risk of occurrence of PUs, prevention of which is a priority for ICU teams caring for critically ill patients. However, the literature is inconclusive regarding the prevalence of PUs among critically ill patients and the associated risk factors. The main objective of this study was to describe the prevalence of PUs among critically ill patients hospitalized in the ICU. Secondary objectives were to describe means of prevention of PUs in the ICU and the characteristics of PUs, and to identify factors either related to the ICU or patient characteristics associated with occurrence of PUs in the ICU.

Eligibility Criteria:
The inclusion criteria were :

* hospitalization in the ICU
* age ≥ 18 years.

The exclusion criterion was:

- refusal to participate in the study by the patient or by the patient's family when the patient was unable to consent.
ELVR in PH Patients With Severe Emphysema

The purpose of this study is to investigate the effect of endoscopic valve implantation in patients with COPD and PH on hemodynamics, symptoms, exercise tolerance and quality of life in 10 patients in a prospective study. An improvement of objective parameters may also have a prognostic significance

So far there is no treatment of COPD in addition to the established treatment of concomitant PH. Administration of PH-specific medication outside of clinical trials is not recommended in new guidelines for PH of the ERS/ESC. The influence of endobronchial valve implantation on the PH has not been studied in detail. The purpose of this study is to investigate the effect of endoscopic valve implantation in patients with COPD and PH on hemodynamics, symptoms, exercise tolerance and quality of life in 10 patients in a prospective study. An improvement of objective parameters may also have a prognostic significance

Eligibility Criteria:
Inclusion Criteria:

* signed patient consent form
* men and women \>30 years
* Clinically indicated endoscopic lung volume reduction
* Pulmonary hypertension according to Group 3.1 of the Dana Point classification
* Severe pulmonary emphysema
* FEV1 \<45%
* RV\> 150%
* TLC\> 100%
* Maximum of medical therapy according to GOLD
* heterogeneous emphysema
* Detected in the HR-CT
* Confirmation of the heterogeneity of emphysema by computer-assisted quantification (YACTA ®)
* stable COPD
* No exacerbation in the last 8 weeks
* Cortisone dose \<20 mg prednisolone equivalent
* Non-or ex-smoker
* Nicotine abstinence\> 4 months
* Actual CoHb \<2.5%
* Diagnosis of pulmonary hypertension (PH), invasively diagnosed by right heart catheterization:
* Mean pulmonary arterial pressure (mPAP)\> 25 mmHg
* Pulmonary capillary wedge pressure (PCWP) \<15 mmHg
* Pulmonary vascular resistance (PVR)\> 320 dyne \* sec \* cm-5

Exclusion Criteria:

* PH of Group 1, 2, 4, 5 of the Dana Point Classification
* Previous operations
* s/p Lung resection (lobectomy / pneumonectomy)
* s/p endoscopic lung volume resection
* significant bronchiectasis
* Sputum volume\> 4 tablespoons / day
* Severe cardiac comorbidities:
* s/p myocardial infarction in the last 6 weeks
* Congestive heart failure
* Cardiomyopathy with highly impaired LVF
* Clopidogrel in long-term medication
* Respiratory insufficiency: PaCO2 mmHg at rest\> 55
* current pregnancy
Neuromuscular Electrical Stimulation and Physical Function in Older Adults

The purpose of this placebo controlled clinical trial is to examine the effects of of neuromuscular electrical stimulation (NMES) training on physical activity, muscle function, self-efficacy, and blood markers \[e.g., brain-derived neurotrophic factor (BDNF)\] in older adults.

It is hypothesized that 4-weeks of NMES will increase 1) physical activity, 2) muscle function, 3) self-efficacy, and 4) BDNF in older adults.

Sarcopenia is a destructive progressive cycle of impaired physical function resulting in loss of muscle mass, strength, and self-confidence in ability to perform physical activities, compounded by difficulty walking and ultimately reduced physical activity levels for many older adults. Neuromuscular electrical stimulation (NMES) is a common therapeutic modality used to create involuntary muscle contractions as a means to increase muscle strength, and may be an effective treatment for improving muscle function and physical activity levels in older adults with sarcopenia. Thus, it is critical to explore viable and effective alternative therapies to increase physical activity. The goal of the investigators' is to determine the effectiveness of neuromuscular electrical stimulation (NMES) at increasing physical activity and related biological, psychological, and muscle function factors. This placebo controlled clinical trial will use a pre-test - post-test randomized experimental design.

Older healthy adults (60 and older) will participate in this study. Participants will undergo 4 weeks of neuromuscular electrical stimulation (NMES) training. Participants will be randomized into the one of two groups 1) NMES-millicurrent or 2) NMES microcurrent. Participants will undergo pre- and post-training testing for muscle function, physical function, and psychological variables related to physical activity. Blood samples will also be obtained pre- and post-training.

Eligibility Criteria:
Inclusion Criteria:

* generally healthy men and women
* ages 60 and older

Exclusion Criteria:

* 1) they have participated in regular resistance training exercise or physical rehabilitation of the lower extremity within 2 months of the study
* 2) contraindicating conditions for electrical stimulation are present (i.e., swollen, infected or inflamed areas including open wounds, or painful areas on the lower limbs, implanted electronics including cardiac pacemakers, electronic infusion pumps, implanted stimulators, or surgical hardware in the lower limbs)
* 3) they have current knee injury or knee pain
* 4) have a neuromuscular disease
* 5) currently taking insulin for diabetes regulation
* 6) they have a history of seizures
Study of a Cohort of Cases of Synovial Sarcoma Treated in the Orthopedic Surgery and Traumatology Department of the Hospital de Sant Pau Between 1983 and 2016

The main objectives of this study are the following: to describe the prognostic factors of survival of synovial sarcoma in patients treated by the orthopedic surgery unit oncologic of the orthopedic surgery and traumatology service of the Hospital de Sant Pau during the years 1983-2016.

Another objectives of this Study are:

To analyze exhaustively a series of cases of synovial sarcoma (as an example of classic subtype of soft tissue sarcoma) to analyse the complementary tests performed and their evolution over time.

To analyse the results of surgical treatment and adjuvant therapies in synovial sarcoma and its evolution over time.

To study the prognostic factors dependent on the patient and the applied therapeutics.

To establish a results-based treatment and follow-up algorithm for patients diagnosed with synovial sarcoma.

To describe the epidemiological characteristics of the group of patients in the study.

To evaluate the overall survival and disease-free survival as well as the mortality of the disease.

To assess the rate of local recurrence and remote dissemination of synovial sarcomas in the series.

To demonstrate the influence of neoadjuvant chemotherapy and radiotherapy in the treatment of the tumor.

Conduct a study by age group with respect to the influence on patient survival. To carry out a study by tumor-sized groups with respect to the influence on the survival of the patients.

To carry out a chronological study on the influence of the advances in the treatments on the survival of the patients.

Compare the results obtained with the published literature.

Eligibility Criteria:
Inclusion Criteria:

The inclusion criteria were: diagnosed cases of synovial sarcoma by the service of pathological anatomy and treated by unit orthopedic surgery oncology, in location of limbs, paravertebral trunk and/or pelvis. We studied the complete medical history of the cases available for the analysis and with a minimum follow-up of 12 months.

Exclusion Criteria: